Product Images Lurasidone Hydrochloride

This is a pharmaceutical label for Lurasidone Hydrochloride Tablets. It contains information on dosage, storage instructions, and precautions. It emphasizes that the medication guide should be dispensed to each patient and advises keeping the medication out of reach of children. There is also a warning to contact a doctor or poison control in case of accidental ingestion. The label mentions that the tablets were manufactured by Pramacatcds United in the United States.*

This is a medication description for Lurasidone Hydrochloride Tablets. Each film-coated tablet contains 120mg of the medication. The dosage instructions are not provided in this excerpt and should be obtained from the package insert. The medication is manufactured by Intas Pharmaceuticals Limited in Ahmedabad, India, and is distributed by Accord Healthcare in Durham, NC. The recommended storage temperature is between 15-30°C (59-86°F). The medication guide should be provided to each patient by the pharmacist. The NDC number for this product is 16729-350-10.*

This is a medication description for Lurasidone Hydrochloride tablets containing 20mg of the active ingredient. The dosage and usage instructions are provided in the package insert. The tablets should be stored at a temperature range of 15°C to 30°C (59°F to 86°F). The tablets are manufactured by Intas Pharmaceuticals Limited in Ahmedabad, India and distributed by Accord Healthcare, Inc. The medication guide enclosed with the tablets should be dispensed to each patient. The NDC code for the tablets is 16729-346-10.*

This is a medication that comes in the form of a film-coated tablet. Each tablet contains 40 mg of Lurasidone Hydrochloride. The dosage and use information is located in the package insert. The tablets should be stored at room temperature, between 15°C to 30°C (59°F to 86°F). It is manufactured by Intas Pharmaceuticals Limited in Ahmedabad, India and is distributed by Accord Healthcare, Inc. in Durham, NC. Pharmacists are advised to dispense the enclosed medication guide to each patient.*

This is a medication guide for Lurasidone Hydrochloride tablets. The recommended dosage and use of this medication can be found in the package insert. It is important to keep this medication out of reach of children and seek medical attention in case of accidental ingestion. The usual adult dosage is one tablet per day. The medication should be stored between 15-30°C. The document contains information for pharmacists and specifies that the medication guide should be included with each prescription. The manufacturer is listed as Rosor Hesteare. The document includes an identification number, DG 16720-348-48, but does not provide any other useful information.*

Each tablet contains 60 mg of Lurasidone Hydrochloride for treating certain mental/mood disorders. Dosage and usage are advised to be checked from the package insert provided. The tablets should be stored at 25°C (77°F) with allowed excursions from 15°C to 30°C (59°F to 86°F), and a pharmacist should provide each patient with an enclosed Medication Guide. The manufacturer of the tablets is Intas Pharmaceuticals Limited based in Ahmedabad, India, and they are distributed in the US by Accord Healthcare, Inc. The medication is available in a pack of 30 coated tablets.*

This is a pharmaceutical product for Lurasidone Hydrochloride Tablets. The package contains 100 tablets and it is only available on prescription. The recommended dosage is one tablet per day, and the storage temperature is between 15 and 30 degrees Celsius. It is important to keep this medication away from children and in case of accidental ingestion, a physician or pharmacist should be contacted immediately. The text also includes information for pharmacists to provide a Medication Guide to each patient.*

Impact of other drugs on Lurasidone Pharmacokinetics(PK) is a study that reports the effects of different drugs on the way lurasidone is processed in the body (PK). The study includes various interacting drugs with their fold changes and 90% confidence intervals (CI) on CYP3A4 inhibitors, including Strong CYP3A4 Tahibitor (Ketoconazole 400mg per day), Moderate CYP3A4(p450) inhibitor (Diliszem 240 mg per day), Strong CYPIAU Inducer (Rifampin 600 mg per day), and Lithium 600 mg BID. This study measures the changes relative to lurasidone alone.*

This text appears to represent output from statistical analysis, specifically displaying the fold change and 90% confidence interval for a variable named "T4". It is possible that this is related to a scientific experiment or medical study, but without additional context it is difficult to determine the exact significance of these results.*